CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
personal-finance
CSL: Why I’m still holding
markets
Market Minute: Reporting Season, Part 2
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,140.50 | 11.00 | 0.12% |
CAC 40 | 7,674.78 | 24.14 | -0.31% |
DAX 40 | 23,596.98 | 173.35 | -0.73% |
Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
FTSE 100 | 9,208.21 | 8.66 | -0.09% |
HKSE | 25,417.98 | 359.47 | 1.43% |
NASDAQ | 21,700.39 | 7.30 | -0.03% |
Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
S&P 500 | 6,481.50 | 20.58 | -0.32% |
S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
SSE Composite Index | 3,812.51 | 46.64 | 1.24% |